• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Cytokinetics To Present at 2026 RBC Global Healthcare Conference

    GLOBENEWSWIRE

    Cytokinetics Closes $805M Public Offering With Full Underwriter

    GLOBENEWSWIRE

    Cytokinetics` Myqorzo succeeds in landmark cardiomyopathy trial

    FIERCE PHARMA

    Cytokinetics Unveils Q1 2026 Financials And Business Update

    GLOBENEWSWIRE

    Cytokinetics Announces Proposed Public Offering Of Common Stock

    GLOBENEWSWIRE

    Cytokinetics to Reveal ACACIA-HCM Phase 3 Aficamten Data May 5

    GLOBENEWSWIRE

    Cytokinetics Reveals Nine Presentations At ESC Heart Failure 2026

    GLOBENEWSWIRE

    Cytokinetics To Announce First Quarter Results On May 5, 2026

    GLOBENEWSWIRE

    Cytokinetics Joins 25th Needham Healthcare Conference

    GLOBENEWSWIRE

    Cytokinetics Issues Inducement Grants Per Nasdaq LR 5635(C)(4)

    GLOBENEWSWIRE

    Cytokinetics Announces 4 Presentations at ACC Scientific Session

    GLOBENEWSWIRE

    Cytokinetics To Participate In March Investor Conferences

    GLOBENEWSWIRE

    Cytokinetics Unveils Q4 2025 Financials And Business Update

    GLOBENEWSWIRE

    Cytokinetics To Report Q4 Results On Feb 24, 2026

    GLOBENEWSWIRE

    Cytokinetics Reveals Eighth Annual Communications Grant Awardees

    GLOBENEWSWIRE

    Cytokinetics, Sydney McLaughlin-Levrone Raise HCM Awareness

    GLOBENEWSWIRE

    Cytokinetics Launches MYQORZO for Obstructive HCM Cardiomyopathy

    GLOBENEWSWIRE

    Cytokinetics Issues Inducement Grants Per Nasdaq LR 5635(C)(4)

    GLOBENEWSWIRE

    Orsini Selected as Pharmacy Partner for Cytokinetics`s MYQORZO

    PR NEWSWIRE

    Caremed Chosen As National Specialty Pharmacy For MYQORZO

    GLOBENEWSWIRE

    Cytokinetics To Present At J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    Cytokinetics’ Myqorzo Receives Approval in US

    FDA

    US FDA Approves Cytokinetics` Heart Disease Drug

    PRESS RELEASE

    NMPA Approves Aficamten for Hypertrophic Cardiomyopathy

    GLOBENEWSWIRE

    Cytokinetics Issues Inducement Grants Per Nasdaq LR 5635(C)(4)

    GLOBENEWSWIRE

    Cytokinetics Announces Positive CHMP Opinion of Myqorzo

    GLOBENEWSWIRE

    Cytokinetics Doesn`T Want Big Pharma Help To Overtake Camzyos

    FIERCE PHARMA

    Cytokinetics Issues Inducement Grants Per Nasdaq LR 5635(C)(4)

    GLOBENEWSWIRE

    Cytokinetics Backs American Heart Association Initiative

    GLOBENEWSWIRE

    Cytokinetics Presents MAPLE-HCM Data at 2025 HCM, AHA Meetings

    GLOBENEWSWIRE

    Cytokinetics Unveils Q3 2025 Financials & Business Results

    GLOBENEWSWIRE

    Cytokinetics To Participate In November Investor Conferences

    GLOBENEWSWIRE

    Cytokinetics To Present At HCM & AHA Scientific Sessions 2025

    GLOBENEWSWIRE

    Cytokinetics To Report Q3 Results On Nov 5, 2025

    GLOBENEWSWIRE

    Cytokinetics Issues Inducement Grants Per Nasdaq LR 5635(C)(4)

    GLOBENEWSWIRE

    Cytokinetics Present Aficamten Data At HFSA Scientific Meeting

    GLOBENEWSWIRE

    Cytokinetics Calls For Proposal For Annual Communications Program

    GLOBENEWSWIRE

    Cytokinetics to Present Thrice at HFSA Annual Meeting 2025

    GLOBENEWSWIRE

    Cytokinetics Announces Inducement Grants Under Nasdaq 5635(C)(4)

    GLOBENEWSWIRE

    Cytokinetics Proposes $550M Convertible Senior Notes Placement

    GLOBENEWSWIRE

    Cytokinetics Unveils Aficamten Data at ESC Congress 2025

    GLOBENEWSWIRE

    Cytokinetics` Drug Effective for Heart Symptoms than Std of Care

    REUTERS

    Cytokinetics to Participate in September Investor Conferences

    GLOBENEWSWIRE

    Cytokinetics Reveals Five Aficamten Presentations at ESC Congress

    GLOBENEWSWIRE

    Cytokinetics Appoints Jim Daly to Director Board

    GLOBENEWSWIRE

    Cytokinetics Grants Inducements Under Nasdaq Rule 5635(c)(4)

    GLOBENEWSWIRE

    Cytokinetics Reports Q2 2025 Financials, Updates on Business

    GLOBENEWSWIRE

    Cytokinetics Announces Q2 Results on August 7, 2025

    GLOBENEWSWIRE

    Cytokinetics grants inducements under Nasdaq Listing Rule

    GLOBENEWSWIRE

    Cytokinetics Unveils Five Aficamten Presentations at 2025

    GLOBENEWSWIRE

    Cytokinetics Announces Inducement Grants for Nasdaq Listing Rule

    GLOBENEWSWIRE

    Cytokinetics Calls for Annual Corporate Giving Proposals

    GLOBENEWSWIRE

    Cytokinetics at Jefferies Global Healthcare Conference

    GLOBENEWSWIRE

    Cytokinetics Presents Data on Aficamten at ESC Heart Failure 2025

    GLOBENEWSWIRE

    Cytokinetics Announces Inducement Grants Under Nasdaq Rule

    GLOBENEWSWIRE

    Cytokinetics Hosts Symposium on Muscle Biology Landscape

    GLOBENEWSWIRE

    Cytokinetics Announces Positive Topline Results From MAPLE-HCM

    GLOBENEWSWIRE

    Cytokinetics to Present at ESC Heart Failure 2025 Congress

    GLOBENEWSWIRE

    Cytokinetics to Hold Annual Meeting of Stockholders

    GLOBENEWSWIRE

    Cytokinetics Reports Q1 2025 Financial Results and Business Update

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.